Daclatasvir Dihydrochloride Patent Expiration
Daclatasvir Dihydrochloride is used for treating hepatitis C virus infections. It was first introduced by Bristol-Myers Squibb Co
Daclatasvir Dihydrochloride Patents
Given below is the list of patents protecting Daclatasvir Dihydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Daklinza | US8629171 | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt | Jun 13, 2031 | Bristol-myers Squibb |
| Daklinza | US8329159 | Hepatitis C virus inhibitors | Jul 24, 2029 | Bristol-myers Squibb |
| Daklinza | US8642025 | Hepatitis C virus inhibitors | Aug 11, 2027 | Bristol-myers Squibb |
| Daklinza | US8900566 | Hepatitis C virus inhibitors | Aug 08, 2027 | Bristol-myers Squibb |
| Daklinza | US9421192 | Hepatitis C virus inhibitors | Aug 08, 2027 | Bristol-myers Squibb |
Daclatasvir Dihydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List